• 新闻与活动

    学术成果

Current State-of-the-art In-house and Cloud-Based Applications of Virtual Polymorph Screening of Pharmaceutical Compounds: A Challenging Case of AZD1305

Cryst. Growth Des. 2021, 21, 4, 1972–1983

We demonstrate the successful application of the state-of-the-art AstraZeneca in-house and XtalPi cloud-based virtual polymorph screening workflows in support of stable form selection of crystalline oxabispidine AZD1305, a pharmaceutical compound. Experimental solid form screening had found two polymorphic forms, A and B, with physical stabilities that appeared to be extremely close at ambient temperature. Such observation may make experimental and in silico support of the solid form selection a challenging task. Both computational approaches correctly predicted the ranking and geometry of the stable form B at 0 K. This level of information would be important and sufficient for project support at the late discovery stage. However, metastable form A was predicted by both workflows to be considerably less stable than form B, separated by multiple virtual forms in the lattice energy landscapes. In order to account for the experimentally observed close physical stabilities of forms A and B at ambient temperature, calculation of the free-energy landscape was performed using pseudo-supercritical path method. This allowed the demonstration that, while form B is significantly more stable at 0 K, the two forms display a very close physical stability at ambient temperature. The current work highlights the importance of using advanced virtual polymorph screening to get a more comprehensive insight into identifying the most stable form of a pharmaceutical compound under different experimental conditions.

想继续了解更多?

联系我们

我们期待您的留言

让我们知道如何为您提供帮助,我们团队将24小时内与您联系!

姓名
电话
邮箱
国家/地区
北京市
天津市
上海市
重庆市
河北省
山西省
辽宁省
吉林省
黑龙江省
江苏省
浙江省
安徽省
福建省
江西省
山东省
河南省
湖北省
湖南省
广东省
海南省
四川省
贵州省
云南省
陕西省
甘肃省
青海省
台湾省
内蒙古自治区
广西壮族自治区
西藏自治区
宁夏回族自治区
新疆维吾尔自治区
香港特别行政区
澳门特别行政区
从事行业
小分子药物研发
抗体药物研发
CRO/CDMO
投融资机构
高校/研究院所/医院
园区
生物医药产业
感兴趣的业务
小分子药物发现
抗体药物发现
药物固体形态研发
化学合成服务(含自动化合成)
实验室自动化解决方案
所在公司
是否需要业务人员跟进?
暂不需要
验证码

我已阅读并同意 晶泰科技隐私政策法律声明